Cargando…
SARS-CoV-2 vaccination and phase 1 cancer clinical trials
Autores principales: | Yap, Timothy A, Siu, Lillian L, Calvo, Emiliano, Lolkema, Martijn P, LoRusso, Patricia M, Soria, Jean-Charles, Plummer, Ruth, de Bono, Johann S, Tabernero, Josep, Banerji, Udai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906739/ https://www.ncbi.nlm.nih.gov/pubmed/33571468 http://dx.doi.org/10.1016/S1470-2045(21)00017-6 |
Ejemplares similares
-
Searching for treatments for non-G12C-KRAS mutant cancers
por: Guo, Christina, et al.
Publicado: (2021) -
A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic
por: Tiu, Crescens, et al.
Publicado: (2020) -
Increasing operational and scientific efficiency in clinical trials
por: Kelly, Deirdre, et al.
Publicado: (2020) -
Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre
por: O’Carrigan, Brent, et al.
Publicado: (2018) -
Designing circulating tumor DNA-based interventional clinical trials in oncology
por: Araujo, Daniel V., et al.
Publicado: (2019)